CA2476454A1 - Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires - Google Patents

Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires Download PDF

Info

Publication number
CA2476454A1
CA2476454A1 CA002476454A CA2476454A CA2476454A1 CA 2476454 A1 CA2476454 A1 CA 2476454A1 CA 002476454 A CA002476454 A CA 002476454A CA 2476454 A CA2476454 A CA 2476454A CA 2476454 A1 CA2476454 A1 CA 2476454A1
Authority
CA
Canada
Prior art keywords
carbon atoms
alkyl
hydrogen
independently
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002476454A
Other languages
English (en)
Inventor
Hans-Jochen Lang
Heinz-Werner Kleemann
Stefan Werner Schneider
Hans Oberleithner
Andre Niemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2476454A1 publication Critical patent/CA2476454A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs de l'échangeur chlorure-bicarbonate pour traiter des affections thrombotiques et inflammatoires. Des inhibiteurs de l'échangeur chlorure-bicarbonate sodium-dépendant présentent un effet inhibiteur sur la sécrétion du facteur de von Willebrand. Ces inhibiteurs peuvent de ce fait s'utiliser pour traiter des affections thrombotiques et inflammatoires.
CA002476454A 2002-02-14 2003-02-05 Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires Abandoned CA2476454A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10206354A DE10206354A1 (de) 2002-02-14 2002-02-14 Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
DE10206354.0 2002-02-14
PCT/EP2003/001100 WO2003068224A2 (fr) 2002-02-14 2003-02-05 Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires

Publications (1)

Publication Number Publication Date
CA2476454A1 true CA2476454A1 (fr) 2003-08-21

Family

ID=27634996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002476454A Abandoned CA2476454A1 (fr) 2002-02-14 2003-02-05 Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires

Country Status (10)

Country Link
EP (1) EP1476154A2 (fr)
JP (1) JP2005525338A (fr)
AR (1) AR038837A1 (fr)
AU (1) AU2003208792A1 (fr)
BR (1) BR0307637A (fr)
CA (1) CA2476454A1 (fr)
DE (1) DE10206354A1 (fr)
MX (1) MXPA04007007A (fr)
TW (1) TW200306808A (fr)
WO (1) WO2003068224A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013011188B1 (pt) 2010-11-05 2022-01-04 Senomyx, Inc Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto
EP3356356B1 (fr) 2015-10-01 2021-05-26 Firmenich Incorporated Composés utiles en tant que modulateurs de trpm8

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19804251A1 (de) * 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
AU2003208792A1 (en) 2003-09-04
BR0307637A (pt) 2005-01-04
MXPA04007007A (es) 2004-10-11
EP1476154A2 (fr) 2004-11-17
WO2003068224A3 (fr) 2003-12-24
DE10206354A1 (de) 2003-08-28
AR038837A1 (es) 2005-01-26
WO2003068224A2 (fr) 2003-08-21
JP2005525338A (ja) 2005-08-25
TW200306808A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
US5192772A (en) Therapeutic agents
US20060025401A1 (en) Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
BRPI0620641A2 (pt) usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
CA2515102A1 (fr) Compositions pharmaceutiques comportant des derives thieno[2,3-c]pyridine et utilisation de ces compositions
CN1274281A (zh) 单独的或与抗血小板聚集药物联合的Xa因子抑制剂
JP4212114B2 (ja) 抗血栓剤としてのｐ１，ｐ４―ジチオ―ｐ２―ｐ３―モノクロロメチレン５’，５’’’―ジアデノシン ｐ１，ｐ４―テトラホスフェート
JP2009538846A5 (fr)
CZ298542B6 (cs) Použití derivátu hydroxylaminu k príprave léciva pro lécbu a prevenci nemocí spojených s dysfunkcí vaskulárních endoteliálních bunek a farmaceutický prípravek tyto látky obsahující
CA2476454A1 (fr) Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires
WO2000057914A1 (fr) Agents permettant d'abaisser la tension oculaire
US6335330B1 (en) Crystalline pharmaceutical product
US20040097583A1 (en) Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
JP2005522412A (ja) 血栓塞栓性疾患および腫瘍の処置のための凝固因子Ｘａの阻害剤としてのフェノキシ−Ｎ−［４−（１，１−ジオキソイソチアゾリジン−２−イル）フェニル］−バレルアミドおよび他の化合物の誘導体
CA2476446A1 (fr) Utilisation d'inhibiteurs de l'antiporteur ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires
KR20040044514A (ko) 항혈전약과 피라졸론 유도체의 조합 약제
US20200206235A1 (en) 6-chromanol derivatives for use as a medicament
KR100782246B1 (ko) 항혈전제와 항혈소판 응집제의 조합체
RU2195273C2 (ru) Фармацевтические продукты для лечения и профилактики заболеваний, появляющихся в результате повреждения эндотелиальных клеток сосудов
KR0135034B1 (ko) 신규한 2-클로로-3-아릴아미노-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 혈소판 응집억제제로서의 용도
EP1275385A1 (fr) Remedes aux maladies associees aux lesions stenosees de vaisseaux sanguins
US10517850B2 (en) Combination of TAFIa inhibitor with plasminogen activator
ZA200109006B (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor.

Legal Events

Date Code Title Description
FZDE Dead